Prime Medicine was founded to bring the promise of gene editing to patients. We use Prime Editing, a next-generation technology that can “search and replace” to restore normal genetic function almost anywhere in the genome. Prime Editing searches to find the precise place in the genome to edit and replaces the segment of faulty DNA with a correct copy of DNA. A single Prime Editor can correct the individual mutations found across patients, meaning Prime Editing can potentially address more than 90 percent of known disease-causing genetic mutations.

We envision a world where this technology can cure, halt, and ultimately prevent genetic diseases, providing lifelong benefit to patients. Prime Medicine offers the opportunity to shape the future of gene editing and transform how medicines are used to treat disease. Realizing the promise of Prime Editing requires a talented team with diversity of viewpoints and expertise. We’re building a group of dedicated, scientifically curious individuals who are passionate about helping patients live longer, healthier lives.

Biotechnology

Prime Medicine

Keith Gottesdiener

Jennifer Gori

Aaron Chang

Alexandria Petrusich

Ze (Cindy) Liu

Yune Kunes

Yi Pu

Robert Greene

Jean Marzilli

John R. Hadcock, Ph.D.

Chris Bell

Barrett Nehilla

Anita R.

Fubao Wang

Meredith Goldwasser

Mohammed Asmal

Richard Brudnick

Carman Alenson

Jeremy Duffield

Karen Brown

Ann Lee

Niamh Alix

Andrew Anzalone

The leadership team at Prime Medicine has a history of experience in the pharmaceutical industry, with a focus on accounting and finance. The team is composed of members who have served in executive positions at major pharmaceutical companies, as well as directors and senior managers. They also hold degrees from prestigious universities in economics, business administration, and management science.

Leadership Team

Board of Directors

CEO and Executive Team

Leadership Team

About

Team members

Other teams at Prime Medicine

Board of Directors

CEO and Executive Team